Keyword: Ono Pharmaceutical

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.

Opdivo, the Bristol-Myers cancer drug co-developed with Japan’s Ono, is a global cash cow—but a Nobel winner behind the drug isn't happy with his cut.

Eisai starts pivotal BAN2401 Alzheimer's trial; AZ helps build new life sciences hub in China; Ono secures a chance to license British I-O programs.

Tasuku Honjo wins Nobel Prize for PD-1 research; Legend fires back at CAR-T data fabrication allegation; Takeda alumni demand more on Shire buyout.

Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.

Officials in Japan have moved to swiftly cut the price on two top-selling cancer meds.

BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.

Just a few months after Merck’s monster May for Keytruda, which featured three FDA approvals, the drugmaker is back with another green light.

Merck will pony up $625 million plus royalties on its blockbuster cancer med Keytruda to settle up its patent dispute with Opdivo-maker Bristol-Myers. The royalty stream could be "quite meaningful," one analyst said.